Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136576 | 0.81 | MMP2 (0.47) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18116276 | 0.79 | MAPT (0.49) | RAB9ANPC1L3MBTL1MEN1KMT2A | |
| SCHEMBL27931867 | 0.79 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL4859516 | 0.79 | NPC1 (0.62) | RAB9ANPC1L3MBTL1KMT2ALMNA | |
| SCHEMBL133449 | 0.78 | PTPN1 (0.59) | ALDH1A1MAPT | |
| SCHEMBL9248136 | 0.78 | NPC1 (0.55) | RAB9ANPC1SMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL395103 | 0.77 | GSK3B (0.48) | RAB9ANPC1SMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL1985055 | 0.76 | L3MBTL1 (0.60) | RAB9ANPC1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL18551705 | 0.76 | L3MBTL1 (0.59) | NPC1SMN1; SMN2L3MBTL1MEN1KMT2A | |
| Bicarbonate SCHEMBL27771212 | 0.75 | SMN1; SMN2 (0.51) | RAB9ANPC1SMN1; SMN2L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | PPARG, PPARD, PPARA | RAB9A 3082/4885NPC1 818/4885SMN1; SMN2 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.